Early-stage biotech exits stealth mode with $5.3M funding boost

04/5/2013 | MedCityNews.com

Calif.-based Nurix has emerged from its stealth period with $5.3 million in equity funding from four investors, according to a securities filing. The biotech startup seeks to develop T-cell-specific immunosuppressant drugs for autoimmune diseases.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID